Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement ...

As Roche heads towards an FDA verdict on its CD20xCD3 bispecific Lunsumio for lymphoma before the end of this year, rivals from Regeneron and AbbVie are starting to nip at its heels, with new ...

Triplet therapy, with the inclusion of anti-CD20 antibodies, has further shown promise, they noted, including in the recent GAIA/CLL13 trial. In that study, patients were treated with venetoclax ...

Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep ...

Regeneron has since re-filed the BCMAxCD3 drug in the U.S., and it's now awaiting a July 10 decision target date. With linvoseltamab's delayed arrival in the U.S., the multiple myeloma bispecific ...

Roche's anti-CD20 antibody Gazyva has been on the market for more than a decade as a treatment for blood cancer, but could see a new lease of life if it gets FDA approval to treat kidney disease ...

The second ADC, SGN-CD19A (Seattle Genetics), comprises a humanized anti-CD19 monoclonal antibody conjugated with MMAF using the noncleavable MC, which is the same linker–cytotoxic agent ...

Immunofluorescence (IMF) can demonstrate the presence of antibodies bound in the skin or antibodies circulating in the serum by showing specific green fluorescence under the fluorescent microscope.